A Phase 1b Study of Pembrolizumab (KEYTRUDA) in Combination With REOLYSIN (Pelareorep) and Chemotherapy in Patients With Advanced Pancreatic Adenocarcinoma

Trial Profile

A Phase 1b Study of Pembrolizumab (KEYTRUDA) in Combination With REOLYSIN (Pelareorep) and Chemotherapy in Patients With Advanced Pancreatic Adenocarcinoma

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 11 Oct 2017

At a glance

  • Drugs Pelareorep (Primary) ; Pembrolizumab (Primary) ; Fluorouracil; Folinic acid; Gemcitabine; Irinotecan
  • Indications Adenocarcinoma; Pancreatic cancer
  • Focus Adverse reactions
  • Sponsors Oncolytics Biotech
  • Most Recent Events

    • 06 Oct 2017 Planned End Date changed from 1 Oct 2017 to 1 Mar 2018.
    • 06 Oct 2017 Planned primary completion date changed from 1 Sep 2017 to 1 Jan 2018.
    • 06 Jun 2017 Results (n=11) presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top